Clinical trial · Observational
Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Patients With Advanced Carcinoma
Study on the Correlation Between Thyroid Dysfunction Induced by Anti PD-1 Therapy and Prognosis in Patients With Advanced Carcinoma
NCT05593744CI-TRIAL-00061670completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, we monitored patients with advanced malignant tumors who received anti-PD-1 therapy to observe the characteristic of anti-PD-1 therapy-induced thyroid dysfunction and its correlation with prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Thyroid dysfunction
- description
- Patients had thyroid dysfunction during anti-PD-1 therapy.
- interventionNames
- Other: no intervention
- label
- No thyroid dysfunction
- description
- Patients didn't have thyroid dysfunction during anti-PD-1 therapy.
- interventionNames
- Other: no intervention
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- Through study completion, an average of 17 weeks
- description
- The time between initiation of anti-PD-1 therapy and disease progression or death, whichever came first.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Eighteen years or older * Confirmed diagnosis of malignancy * Received anti-PD-1 therapy Exclusion Criteria: * Thyroid malignancy or history of thyroid malignancy * Thyroid dysfunction before anti-PD-1 therapies * Previous ICIs treatment * Less than 2 cycles of anti-PD-1 treatment * No thyroid function monitoring during treatment * Known pituitary disease * Pregnancy.
References
Publications (1)
- DERIVEDLu Y, Li Q, Xu L, Zheng Y, Wang Y, Liu Y, Zhang R, Liao L, Dong J. Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma. J Cancer Res Clin Oncol. 2023 Dec;149(18):16501-16510. doi: 10.1007/s00432-023-05364-z. Epub 2023 Sep 15. PMID 37715029